Suvarna Garge (Editor)

Rufinamide

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Covid-19
MedlinePlus  a609001
ATC code  N03AF03 (WHO)
Molar mass  238.19 g/mol
Routes of administration  By mouth (tablets)
CAS ID  106308-44-5
Rufinamide
AHFS/Drugs.com  Consumer Drug Information
License data  EU EMA: Inovelon US FDA: Rufinamide
Pregnancy category  US: C (Risk not ruled out)

Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.

Rufinamide was approved by the US Food and Drug Administration on November 14, 2008 as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults. Its official FDA-approved labeling does not mention use in the treatment of partial seizures inasmuch as clinical trials submitted to the FDA were marginal. However, several recent clinical trials suggest that the drug has efficacy for partial seizures It is marketed under the brand name Banzel. It is also marketed in the European Union under the brand name Inovelon.

The mechanism of action of rufinamide is unknown. There is some evidence that rufinamide can modulate the gating of voltage-gated sodium channels, a common target for antiepileptic drugs. A recent study indicates subtle effects on the voltage-dependence of gating and the time course of inactivation in some sodium channel isoforms that could reduce neuronal excitability. However, this action cannot explain the unique spectrum of activity of rufinamide.

References

Rufinamide Wikipedia


Similar Topics
Jeremy Boone
Kana Oyama
Laetisha Scanlan
Topics
 
B
i
Link
H2
L